Please use this identifier to cite or link to this item:
https://hdl.handle.net/11055/456
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Barratt, Daniel T | |
dc.contributor.author | Cox, Hannah K | |
dc.contributor.author | Menelaou, Andrew | |
dc.contributor.author | Yeung, David T | |
dc.contributor.author | White, Deborah L | |
dc.contributor.author | Hughes, Timothy P | |
dc.contributor.author | Somogyi, Andrew A | |
dc.date.accessioned | 2018-04-08T01:03:49Z | - |
dc.date.available | 2018-04-08T01:03:49Z | - |
dc.date.issued | 2017-08 | |
dc.identifier.citation | Clinical pharmacokinetics 2017-08; 56(8): 977-985 | |
dc.identifier.uri | http://hdl.handle.net/11055/456 | - |
dc.description.abstract | The aims of this study were to determine the effects of the CYP2C8*3 and *4 polymorphisms on imatinib metabolism and plasma imatinib concentrations in chronic myeloid leukaemia (CML) patients. We genotyped 210 CML patients from the TIDELII trial receiving imatinib 400-800 mg/day for CYP2C8*3 (rs11572080, rs10509681) and *4 (rs1058930). Steady-state trough total plasma N-desmethyl imatinib (major metabolite):imatinib concentration ratios (metabolic ratios) and trough total plasma imatinib concentrations were compared between genotypes (one-way ANOVA with Tukey post hoc). CYP2C8*3 (n = 34) and *4 (n = 15) carriers had significantly higher (P < 0.01) and lower (P < 0.01) metabolic ratios, respectively, than CYP2C8*1/*1 (n = 147) patients (median ± standard deviation: 0.28 ± 0.08, 0.18 ± 0.06 and 0.22 ± 0.08, respectively). Plasma imatinib concentrations were consequently > 50% higher for CYP2C8*1/*4 than for CYP2C8*1/*1 and CYP2C8*3 carriers (2.18 ± 0.66 vs. 1.45 ± 0.74 [P < 0.05] and 1.36 ± 0.98 μg/mL [P < 0.05], respectively). CYP2C8 genotype significantly alters imatinib metabolism in patients through gain- and loss-of-function mechanisms. | |
dc.language.iso | eng | |
dc.title | CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. | |
dc.type | Journal Article | |
dc.identifier.journaltitle | Clinical pharmacokinetics | |
dc.identifier.doi | 10.1007/s40262-016-0494-0 | |
dc.description.pubmeduri | https://www.ncbi.nlm.nih.gov/pubmed/27995529 | |
dc.identifier.pubmedid | 27995529 | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Collections: | Scholarly and Clinical |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.